A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 16 Issue 2 September 2022) has been published and includes articles on:

Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations
Rucaparib (Rubraca▼): withdrawal of third-line treatment indication
COVID-19 vaccines and medicines: updates for September 2022
Letters and medicine recalls sent to healthcare professionals in August 2022

To see the latest MHRA Drug Safety Updates in full, visit the GOV.uk website.

The post MHRA Drug Safety Update September 2022 appeared first on PSNC Website.